Geron (GERN) AI Stock Analysis

• Market Cap: $759.64M
• Dividend Yield: N/A
• Average Volume (3M): 8.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 522.13%
• EPS Growth: 62.68%
• Country: US
• Employees: 229
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 638,355,300
• 10 Day Avg. Volume: 7,510,589
• 30 Day Avg. Volume: 8,325,978
• PEG Ratio: 0.84
• Price to Book (P/B): 8.16
• Price to Sales (P/S): 29.70
• P/FCF Ratio: -10.43
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 4.27
• Enterprise Value/Gross Profit: 4.95
• Enterprise Value/Ebitda: -17.45
• 1Y Price Target: $4.00
• Price Target Upside: 236.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.11
• Revenue Forecast (FY): $186.64M

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-15.97% Downside)

Geron's overall score is driven by financial challenges, including negative profitability and cash flow issues. Technical indicators show bearish momentum, and valuation metrics are poor. The earnings call provides some positive insights, but significant challenges remain.

Positive Factors

Revenue Growth

The revenue growth indicates that Geron is expanding its market presence and product adoption, which is crucial for a clinical-stage company transitioning to commercialization.

Strong Financial Position

A strong cash position provides Geron with the financial flexibility to invest in R&D and commercialization efforts, supporting long-term growth and stability.

Increased Prescribing Accounts

Expanding the number of prescribing accounts enhances market penetration and potential revenue streams, indicating growing acceptance of Geron's therapies.

Negative Factors

Profitability Challenges

Ongoing profitability issues suggest high operational costs, which could hinder Geron's ability to achieve sustainable financial performance without significant cost management.

Cash Flow Issues

Persistent cash flow challenges may limit Geron's ability to fund operations and growth initiatives, potentially impacting its long-term viability.

Decline in RYTELO Demand

The decline in demand for RYTELO highlights challenges in maintaining product momentum, which could affect future revenue growth if not addressed.

Geron Business Overview & Revenue Model

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

How the Company Makes Money

Geron generates revenue primarily through the development and commercialization of its therapeutic products. The company does not currently have any approved products on the market, so its revenue streams are largely dependent on milestone payments from partnerships and collaborations, particularly with larger pharmaceutical companies. These partnerships may involve upfront payments, milestone payments tied to development progress, and potential royalties on future sales of successful therapies. Additionally, Geron may receive funding through government grants or research collaborations aimed at advancing its clinical trials. The company's ability to generate revenue will significantly depend on the successful progression of its clinical candidates, securing regulatory approvals, and eventual market launch.

Geron Financial Statement Overview

Summary

Geron shows revenue growth but struggles with profitability and cash flow. The high gross profit margin is positive, but negative net income and cash flow issues highlight financial challenges.

Income Statement

Geron's income statement shows a significant improvement in revenue growth with a TTM increase of 11.53%. However, the company continues to face challenges with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains high at 98.03%, indicating strong product profitability, but the overall negative net income suggests high operational costs or other financial burdens.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.47, indicating manageable leverage levels. However, the return on equity is negative, highlighting ongoing profitability challenges. The equity ratio stands at a healthy level, suggesting a solid asset base relative to equity.

Cash Flow

Cash flow analysis reveals a concerning trend with negative operating and free cash flows, and a significant decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. Despite these challenges, the free cash flow to net income ratio is close to 1, suggesting that cash flow aligns with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	183.40M	76.99M	237.00K	596.00K	1.39M	253.00K
Gross Profit	158.11M	75.74M	237.00K	596.00K	1.39M	-49.80M
EBITDA	-44.86M	-154.85M	-174.78M	-134.15M	-111.59M	-76.75M
Net Income	-79.99M	-174.57M	-184.13M	-141.90M	-116.11M	-75.62M
Balance Sheet
Total Assets	567.38M	593.78M	394.08M	190.57M	226.03M	270.73M
Cash, Cash Equivalents and Short-Term Investments	380.53M	406.57M	333.70M	172.75M	183.72M	196.28M
Total Debt	121.92M	121.72M	85.90M	55.75M	55.00M	29.72M
Total Liabilities	318.68M	313.46M	146.13M	110.58M	99.62M	59.78M
Stockholders Equity	248.71M	280.32M	247.95M	80.00M	126.42M	210.95M
Cash Flow
Free Cash Flow	-132.82M	-219.30M	-168.57M	-127.81M	-95.76M	-67.05M
Operating Cash Flow	-132.91M	-218.62M	-167.74M	-127.38M	-95.56M	-66.65M
Investing Cash Flow	-17.41M	-106.00M	-180.32M	62.07M	71.95M	-105.32M
Financing Cash Flow	168.05M	334.37M	362.02M	87.26M	48.56M	168.35M

Geron Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GERN, the sentiment is Positive. The current price of 1.19 is above the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.24, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.34 is Neutral, neither overbought nor oversold. The STOCH value of 63.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GERN.

Geron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANAB	52 Neutral	$1.15B	―	-308.02%	―	196.42%	53.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.69B	―	-129.32%	―	597.19%	0.45%
CRMD	47 Neutral	$760.31M	4.70	75.08%	―	1647.67%	―
GERN	45 Neutral	$759.64M	―	-29.57%	―	522.13%	62.68%
QURE	40 Underperform	$1.70B	―	-165.27%	―	-44.90%	11.49%
AVBP	39 Underperform	$759.04M	-4.66	-51.98%	―	―	-75.31%

Geron Corporate Events

Geron Corporation’s Q3 2025 Financial Performance and Strategic Progress

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing innovative therapies for blood cancer, with its flagship product RYTELO, a telomerase inhibitor, approved for certain anemic conditions. In the third quarter of 2025, Geron Corporation reported a significant increase in net product revenue from RYTELO, reaching $47.2 million, despite a slight decline in demand. The company completed patient enrollment for its Phase 3 IMpactMF clinical trial and strengthened its leadership team, aiming to enhance commercial execution and expand its market presence. Key financial metrics showed a reduction in net loss compared to the previous year, with total revenues significantly increasing from $28.3 million to $47.2 million. Operating expenses rose slightly due to increased investment in research and development and marketing. Looking ahead, Geron Corporation remains optimistic about its strategic initiatives and financial position, with plans to continue expanding RYTELO’s reach and advancing its clinical pipeline, supported by a strong cash position.

Geron Corporation’s Earnings Call: Mixed Sentiments and Future Prospects

The recent earnings call of Geron Corporation presented a mixed sentiment among stakeholders. While there were positive developments such as an increase in prescribing accounts and new patient starts, the company also faced challenges including declining demand and the need for greater awareness and education regarding RYTELO’s use in earlier treatment lines.

Geron Announces Executive Leadership Transitions

On October 10, 2025, Geron Corporation announced the resignation of board member Dr. Gaurav Aggarwal and the decision of Dr. V. Bryan Lawlis not to stand for re-election at the 2026 Annual Meeting. Additionally, on October 15, 2025, executives Andrew J. Grethlein and Jim Ziegler departed from their roles, with Grethlein transitioning to a consulting role to assist with the transition. On October 13, 2025, Geron announced several executive leadership transitions, appointing Ahmed ElNawawi as the new Executive Vice President, Chief Commercial Officer, along with three other seasoned executives to strengthen its leadership team. These changes aim to align the company’s leadership structure with its strategic priorities, focusing on driving growth and maximizing the potential of RYTELO®.

The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.

Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment

Geron Corporation is conducting a Phase 3 clinical study titled ‘A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor.’ The study aims to assess the overall survival of participants with intermediate-2 or high-risk Myelofibrosis who have not responded to JAK-Inhibitor treatment, highlighting its significance in addressing unmet medical needs in this patient population.

Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment

Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants receiving imetelstat compared to those receiving the best available therapy, targeting patients with intermediate-2 or high-risk MF who have not responded to JAK-inhibitor treatment.

Geron Corporation’s Phase 3 Study: A Potential Game-Changer for Myelofibrosis Treatment

Study Overview: Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants treated with imetelstat compared to BAT in patients who have not responded to JAK-inhibitor treatment, highlighting its potential significance in advancing treatment options for this patient group.